Physical Therapists in Brinkley, AR Accepting Medicare
5 Physical Therapists found. Showing 1 - 5
 Drew Crane, DPT Physical Therapist Medicare: Medicare Enrolled Practice Location: 1100 N Main St, Brinkley, AR 72021 Phone: 870-734-9907 |
 Theraskills, P.a. Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1116 N New York St Extension, Brinkley, AR 72021 Phone: 870-734-1155 |
Therapy Zone Incorporated Physical Therapist Medicare: Medicare Enrolled Practice Location: 1214 Hwy 49 North, Brinkley, AR 72012 Phone: 501-804-2304 |
Michael Sayger, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1100 N Main St, Brinkley, AR 72021 Phone: 870-394-7000 Fax: 870-394-7001 |
 Ashley Cockrell Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 1214 Hwy 49 North, Brinkley, AR 72012 Phone: 501-804-2304 |
News Archive
Impax Laboratories settles FLOMAX litigation, to launch generic tamsulosin hydrochloride product
Impax Laboratories, Inc. today announced that it has reached agreement with Astellas Pharma Inc. and Boehringer Ingelheim Pharmaceuticals, Inc. to settle pending U.S. litigation with regard to US Patent No. 4,703,063 for FLOMAX® (generic name: tamsulosin hydrochloride) capsules through the entry of a consent judgment confirming the validity and infringement of the patent. FLOMAX® is a treatment for the functional symptoms of benign prostatic hyperplasia.
Gut microbiota could predict severity of COVID-19
The COVID-19 pandemic is spreading to every corner of the world. But not everyone is falling sick at the same rate. A new study published on the preprint server medRxiv in April 2020 suggests that the composition of the gut microbiome could partially explain the difference in susceptibility. This adds a new dimension to what is currently known about the disease.
SCCA, ProCure to open new proton therapy center for cancer treatment
Seattle Cancer Care Alliance, together with ProCure Treatment Centers Inc., today held its ceremonial groundbreaking on a new proton therapy center in north Seattle that will provide a first-of-its-kind treatment option for cancer patients throughout the Northwest.
Results from HSPPC-96 Phase 2 study against recurrent gliobastoma presented at ASCO 2011
In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.
› Verified 2 days ago
Physical Therapists
Speech-Language Pathologists
Optometrists
Occupational Therapists